Company Announcement No. 1178

Pursuant to section 30 (cf. sections 38-40) of the Danish Capital Markets Act, it is hereby announced that BlackRock, Inc. (BlackRock) has informed DSV A/S (DSV) that BlackRock’s holding of shares/voting rights and other financial instruments in DSV as of 22 October 2026 has exceeded the 5% threshold as follows:

BlackRock’s share capital and voting rights in DSV   Holding in DSV as of 22 October 2026
Share capital and voting rights attached to shares in %   5.03%
Share capital and voting rights through financial instruments in %   0.02%
BlackRock’s total share capital and voting rights in %   5.05%

As of 22 October 2026, BlackRock directly or indirectly controls a total of 12,170,380 shares/voting rights and other financial instruments in DSV, corresponding to 5.05% of the entire share capital and voting rights in DSV.

Contacts
Investor Relations 
Stig Frederiksen, tel. +45 43 20 36 38, stig.frederiksen@dsv.com
Alexander Plenborg, tel. +45 43 20 33 73, alexander.plenborg@dsv.com

Yours sincerely,
DSV A/S

Attachment

COMPANY ANNOUNCEMENT NO 55/2026 – October 26, 2026

On August 17, 2026, Royal Unibrew announced a share buy-back program, cf. company announcement no. 44/2026.

The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of April 16, 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). 

The share buy-back program is expected to be realized in the period from August 18, 2026, to December 18, 2026. The total transaction value of the share buy-backs in the period will not exceed DKK 300m.

The following transactions have been made under the program:

  Number of
Shares
Average purchase price DKK Transaction value, DKK
Accumulated, last announcement 397,657 418.77 166,527,964
October 19, 2026 5,242 430.53 2,256,853
October 20, 2026 5,500 437.25 2,404,857
October 21, 2026 5,500 439.32 2,416,258
October 22, 2026 6,000 441.22 2,647,335
October 23, 2026 6,000 441.01 2,646,052
Total accumulated under the program 397,657 420.05 178,899,319

With the transactions stated above Royal Unibrew owns a total of 2,208,487 shares, corresponding to 4.5% of the share capital. The total amount of shares in the company is 49,300,000, including treasury shares.

For further information please contact:
Flemming Ole Nielsen (Head of Investor Relations)
E-mail: Flemming.Nielsen@royalunibrew.com
Telephone: +45 25 41 68 04

Encl.

Attachments

COMPANY ANNOUNCEMENT NO 55/2026 – October 26, 2026

On August 17, 2026, Royal Unibrew announced a share buy-back program, cf. company announcement no. 44/2026.

The share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of April 16, 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). 

The share buy-back program is expected to be realized in the period from August 18, 2026, to December 18, 2026. The total transaction value of the share buy-backs in the period will not exceed DKK 300m.

The following transactions have been made under the program:

  Number of
Shares
Average purchase price DKK Transaction value, DKK
Accumulated, last announcement 397,657 418.77 166,527,964
October 19, 2026 5,242 430.53 2,256,853
October 20, 2026 5,500 437.25 2,404,857
October 21, 2026 5,500 439.32 2,416,258
October 22, 2026 6,000 441.22 2,647,335
October 23, 2026 6,000 441.01 2,646,052
Total accumulated under the program 397,657 420.05 178,899,319

With the transactions stated above Royal Unibrew owns a total of 2,208,487 shares, corresponding to 4.5% of the share capital. The total amount of shares in the company is 49,300,000, including treasury shares.

For further information please contact:
Flemming Ole Nielsen (Head of Investor Relations)
E-mail: Flemming.Nielsen@royalunibrew.com
Telephone: +45 25 41 68 04

Encl.

Attachments

Canada’s largest credit union strengthens its technology foundation to increase efficiency and support its next phase of growth

Vancity Selects Temenos SaaS to Modernize Core Banking

Canada’s largest credit union strengthens its technology foundation to increase efficiency and support its next phase of growth
Canada’s largest credit union strengthens its technology foundation to increase efficiency and support its next phase of growth

VANCOUVER, Canada and GRAND-LANCY, Switzerland, Oct. 26, 2026 (GLOBE NEWSWIRE) — Temenos (SIX: TEMN), a global leader in banking technology, today announced that Vancity has selected Temenos SaaS to modernize its core banking platform and support its next phase of growth.

Serving the needs of more than 588,000 members across more than three million accounts and reporting CAD $42.4 billion in assets, Vancity is Canada’s largest credit union and one of the country’s most significant member-owned financial institutions.

With Temenos, Vancity will follow a build-and-migrate strategy, enabling it to introduce new digital banking capabilities while progressively modernizing its existing operations. This approach will help Vancity transition to Temenos’ modern SaaS platform at a pace that protects members, operations and business continuity.

The transformation program will support core banking operations across Vancity’s main business lines, including retail deposits, retail lending, corporate banking, and payments. The scope includes Temenos Core, Temenos Payments Hub and Temenos Data Hub.

Deployed on Microsoft Azure, Temenos SaaS will provide Vancity with a scalable and resilient foundation while simplifying the management of its core banking technology and supporting its ESG commitments through a more efficient technology environment.

Wendy Murphy, Chief Technology Officer, Vancity, commented: “Banking is changing, and the technology behind it needs to change too. Moving to Temenos SaaS represents a deliberate shift toward a simpler, more scalable technology foundation that can continuously evolve, allowing Vancity to innovate faster and respond to our members’ changing needs. It means we can spend less time managing complexity and more time investing in better banking experiences for our members.”

Brian DuVal, President, North America, Temenos, said: “Vancity is one of Canada’s most significant financial institutions with a broad and sophisticated banking operation. This program underscores how Temenos’ modern technology platform can help established financial institutions across North America move core banking operations to the cloud while supporting the breadth and complexity of their business.”

Attachment

CONTACT: Scott Rowe
Temenos
+  44 (0) 20 7423 3857
scott.rowe@temenos.com

Canada’s largest credit union strengthens its technology foundation to increase efficiency and support its next phase of growth

Vancity Selects Temenos SaaS to Modernize Core Banking

Canada’s largest credit union strengthens its technology foundation to increase efficiency and support its next phase of growth
Canada’s largest credit union strengthens its technology foundation to increase efficiency and support its next phase of growth

VANCOUVER, Canada and GRAND-LANCY, Switzerland, Oct. 26, 2026 (GLOBE NEWSWIRE) — Temenos (SIX: TEMN), a global leader in banking technology, today announced that Vancity has selected Temenos SaaS to modernize its core banking platform and support its next phase of growth.

Serving the needs of more than 588,000 members across more than three million accounts and reporting CAD $42.4 billion in assets, Vancity is Canada’s largest credit union and one of the country’s most significant member-owned financial institutions.

With Temenos, Vancity will follow a build-and-migrate strategy, enabling it to introduce new digital banking capabilities while progressively modernizing its existing operations. This approach will help Vancity transition to Temenos’ modern SaaS platform at a pace that protects members, operations and business continuity.

The transformation program will support core banking operations across Vancity’s main business lines, including retail deposits, retail lending, corporate banking, and payments. The scope includes Temenos Core, Temenos Payments Hub and Temenos Data Hub.

Deployed on Microsoft Azure, Temenos SaaS will provide Vancity with a scalable and resilient foundation while simplifying the management of its core banking technology and supporting its ESG commitments through a more efficient technology environment.

Wendy Murphy, Chief Technology Officer, Vancity, commented: “Banking is changing, and the technology behind it needs to change too. Moving to Temenos SaaS represents a deliberate shift toward a simpler, more scalable technology foundation that can continuously evolve, allowing Vancity to innovate faster and respond to our members’ changing needs. It means we can spend less time managing complexity and more time investing in better banking experiences for our members.”

Brian DuVal, President, North America, Temenos, said: “Vancity is one of Canada’s most significant financial institutions with a broad and sophisticated banking operation. This program underscores how Temenos’ modern technology platform can help established financial institutions across North America move core banking operations to the cloud while supporting the breadth and complexity of their business.”

Attachment

CONTACT: Scott Rowe
Temenos
+  44 (0) 20 7423 3857
scott.rowe@temenos.com

Bagsværd, Denmark, 26 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 19 October, the following transactions have been made:

  Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 24,315,000   7,075,024,314
19 October 2026 239,994 257.23 61,734,209
20 October 2026 240,006 258.81 62,115,110
21 October 2026 240,000 260.66 62,558,988
22 October 2026 240,000 262.77 63,065,792
23 October 2026 240,000 261.87 62,849,699
Accumulated under the programme 25,515,000   7,387,348,112

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 54,314,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.2% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 23 October 2026, Novo Nordisk has since 4 February 2026 repurchased a total 40,274,179 B shares at an average share price of DKK 277.78 per B share equal to a transaction value of DKK 11,187,348,102.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Nordisk Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com
Novo Nordisk Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Max Ung
+45 3077 6414
mxun@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

Company announcement No 63 / 2026

Attachments

Bagsværd, Denmark, 26 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 19 October, the following transactions have been made:

  Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 24,315,000   7,075,024,314
19 October 2026 239,994 257.23 61,734,209
20 October 2026 240,006 258.81 62,115,110
21 October 2026 240,000 260.66 62,558,988
22 October 2026 240,000 262.77 63,065,792
23 October 2026 240,000 261.87 62,849,699
Accumulated under the programme 25,515,000   7,387,348,112

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 54,314,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.2% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 23 October 2026, Novo Nordisk has since 4 February 2026 repurchased a total 40,274,179 B shares at an average share price of DKK 277.78 per B share equal to a transaction value of DKK 11,187,348,102.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Nordisk Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com
Novo Nordisk Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Max Ung
+45 3077 6414
mxun@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

Company announcement No 63 / 2026

Attachments

Hong Kong, Oct. 26, 2026 (GLOBE NEWSWIRE) — Green Circle Decarbonize Technology Limited (the “Company”) (NYSE American: GCDT), a Cayman Islands holding company that, through its Hong Kong subsidiary, Boca International Limited, develops and manufactures Phase Change Material (PCM-TES) storage systems designed for cooling and heating applications, today announced that NYSE American had contacted the Company regarding recent trading activity in the Company’s ordinary shares.

Although it is the Company’s policy not to comment on unusual market activity or market speculation, in response to NYSE American’s inquiry, the Company confirms that, following appropriate inquiry, it is not aware of any material undisclosed developments relating to its business or operations that would account for the recent trading activity in its ordinary shares.

From time to time, the Company evaluates potential strategic initiatives and financing opportunities in the ordinary course of business. The Company does not comment on market speculation regarding potential transactions, and there can be no assurance that any potential transaction will be pursued or completed. The Company does not intend to comment further on this matter unless disclosure is required under applicable securities laws or NYSE American rules.

The Company will continue to monitor trading activity in its securities and will disclose material information as required by applicable securities laws and NYSE American rules.

About Green Circle Decarbonize Technology Limited

Green Circle Decarbonize Technology Limited is a Cayman Islands holding company operating through its Hong Kong subsidiary, Boca International Limited. The Company is a provider of advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services.

Forward-Looking Statements

Certain statements in this press release constitute forward-looking statements within the meaning of applicable securities laws. These statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections regarding future events that may affect its financial condition, results of operations, business strategy and financial needs. Forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “propose,” “seek,” “should,” “will” and “would,” or similar expressions. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Investors should review the risk factors and other disclosures included in the Company’s registration statements and other filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances or changes in its expectations, except as required by applicable law.

For more information, please contact:

Green Circle Decarbonize Technology Limited

Chief Financial Officer
Email: louis.leung@vbg.com.hk

SHANGHAI, Oct. 26, 2026 (GLOBE NEWSWIRE) — Three days in Wuhu, four very different tests. At the 2026 Chery International User Summit, FREELANDER’s international guests took part in the first test drive of the international variant of FREELANDER 8, on and off road.

The Test Drive Programme

An all-terrain course came first, then an obstacle course with a steep hill-climb ramp, water and cross-axle sections, a paved test course and, on 21 October, SIVP (Super Intelligent Valet Parking). Off road, i-ATS (Intelligent All-Terrain System) let guests choose from nine terrain modes to suit the ground.

Image 2 FREELANDER 8 drives through mud and standing water on the all-terrain course

A guest drives FREELANDER 8 with i-ATS (Intelligent All-Terrain System) at Tuju Campground

What Guests Said

On the steep descent, a guest from Spain said their heart was “still pounding a little bit”, then added: “But I trust the car.” When rain fell on the slope, a guest from Egypt was glad of it: “this is really the torture test for any slope.”

On the paved course, a guest from the United Kingdom found the car “far more comfortable than I had expected.” A guest from Qatar said: “I expected it from everything we heard about the car. But to experience it in real life, it was a different thing.”

The Technology Behind It

Under the relevant test conditions, FREELANDER 8 can climb gradients of up to 70%. Hill Descent Control and Crawl Control help manage the way down. FREELANDER 8’s global validation programme includes a 12-hour extreme rain test.

On cross-axle sections, FREELANDER 8 offers 800 mm of maximum articulation and 240 mm of wheel travel, with the All-Terrain Dual Lock System helping to maintain traction. It can wade through water up to 900 mm deep. These capabilities are subject to the vehicle’s operating limits and appropriate driving conditions.

Image 2 FREELANDER 8 drives through mud and standing water on the all-terrain course

FREELANDER 8 drives through mud and standing water on the all-terrain course

Dual-chamber air suspension with Continuously Controlled Damping (CCD) supports ride comfort. The international left-hand drive version delivers 460 kW of peak power and 662 N·m of peak torque, with 0–100 km/h in 5.8 seconds. Braking comes from six-piston fixed front calipers with 404 mm vented front discs.

In supported parking scenarios, SIVP lets drivers park and recall the car via a smartphone app. It will be available in selected markets, subject to the system’s operating conditions; the driver remains responsible at all times.

What Comes Next

Launch in the United Arab Emirates is expected in the first quarter of 2027. FREELANDER 8 brings together premium heritage, intelligent technology and all-terrain capability. This combination reflects the brand slogan “Beyond the Legend” and its vision of building on its heritage through intelligent innovation and distinctive design.

About FREELANDER

FREELANDER is a British Premium Intelligent All-Terrain Brand, jointly developed by JLR and Chery Group. JLR owns the FREELANDER brand and has established a dedicated FREELANDER Design Hub to lead its design. Chery provides advanced intelligent technology and a top-tier global supply chain. The brand’s global foundation includes more than 5,000 employees, five strategic hubs and fully integrated capabilities spanning design, R&D, manufacturing and global operations.

Media contact
Daniel Bao
freelander.international@mychery.com
https://www.cheryinternational.com/

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/d62eb57a-fd91-4097-bf18-d8af89813f78

https://www.globenewswire.com/NewsRoom/AttachmentNg/4cb39ba5-3569-42b7-aa26-3019aa2f2396

More than 70% of members in the study reported symptom improvement, with the greatest gains among those receiving both personalized coaching and menopause-trained provider care

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced findings from a new clinical outcomes study showing significant improvements in menopause symptoms among members receiving care through its Menopause and Midlife program. The research found that more than 70% of members in the study experienced improvement in their menopause symptoms, with the greatest gains observed among those who received both personalized coaching and care from menopause-trained providers.

The findings, detailed in Progyny’s new white paper, Beyond the Hype: Evidence for a Connected Model of Menopause Care, come during Menopause Awareness Month and as demand for menopause support continues to grow, yet access to evidence-based care remains limited, inconsistent, and difficult to navigate. In an expanding marketplace of menopause solutions offering widely varying levels of clinical support, the research underscores the importance of a connected care model that integrates education, personalized guidance, and specialized clinical care to help women navigate this critical life stage.

“Menopause has historically been underdiscussed and undertreated. Growing awareness is an important step forward, but awareness alone isn’t enough,” said Dr. Janet Choi, Chief Medical Officer, Progyny. “Women need reliable education and access to knowledgeable providers who offer evidence-based care tailored to their individual symptoms, health needs and goals. With so many products and treatments promoted today, employers also need confidence that the benefits they invest in connect employees to care grounded in clinical best practices, tailored to improve their health and well-being.”

Key findings from the study include:

  • More than 70% of members in the study experienced symptom improvement: 70.8% of members reported an overall improvement in menopause symptoms, with an average 7.1-point improvement on the Menopause Rating Scale (MRS), a validated assessment of 11 common symptoms scored in severity on a scale from 0 to 44.
  • Coaching plus menopause-trained provider care was associated with the greatest improvements: Members who received both experienced an average 7.6-point improvement in MRS scores, compared with 3.3 points among those who received coaching alone.
  • Significant improvements were observed across all 11 measured symptoms: Members experienced reductions in hot flashes (52%), vaginal dryness (50%), cardiac symptoms (48%), and depressive mood (45%), among other symptoms.
  • Sleep disturbance fell 42%, addressing a symptom linked to cardiometabolic risk.
  • Women with severe symptoms also experienced meaningful relief: 40.4% of members who initially reported severe symptoms moved into a lower symptom severity category.

Addressing a growing gap in menopause care

Despite increasing attention to menopause in the workplace, many women continue to face challenges finding qualified providers and navigating treatment options. As recently as 2023, fewer than one-third of OB-GYN residency programs included menopause management training, contributing to gaps in specialized care.

These challenges have a direct impact on employee well-being and performance. Research published in Mayo Clinic Proceedings estimated that menopause-related symptoms contribute to $1.8 billion in annual lost productivity in the United States due to missed workdays alone.

Progyny’s findings highlight the potential value of a more comprehensive approach to menopause support. Its Menopause and Midlife program combines evidence-based education, one-on-one coaching from clinically trained Progyny Care Advocates, and access to a curated network of menopause-trained providers. The model is designed to help members understand their symptoms, navigate treatment options, and access appropriate clinical care based on individual needs.

“A few months ago…the only thing I knew about menopause was that hot flashes were involved. While I was having hot flashes, the brain fog and joint pain were more debilitating. I felt like a shell of a human when I first contacted Progyny. [My Progyny Care Advocate] was very supportive, kind, understanding, and patient. She oriented me on my benefit and connected me with [a menopause provider]. I have a new lease on life. I feel so fortunate,” said one Progyny member.

The full white paper, Beyond the Hype: Evidence for a Connected Model of Menopause Care, is available here.

About Progyny

Progyny is a global leader in women’s health and family building solutions, trusted by leading employers, health plans, and benefit purchasers worldwide. Through its comprehensive and personalized approach, Progyny supports members across fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being journeys. Progyny combines differentiated clinical care, integrated pharmacy support through Progyny Rx®, and personalized guidance from Progyny Care Advocates® to deliver improved member experiences and better health outcomes. For more information, visit www.progyny.com.

About the study

The analysis was a retrospective longitudinal review of members enrolled in Progyny’s Menopause and Midlife program during 2025–2026. The clinical outcomes sample included 179 members who completed an initial Menopause Rating Scale assessment during their first coaching call and a follow-up assessment an average of 109 days later. Findings reflect observed associations within the study population and do not establish causation.

For Further Information, Please Contact:

Media:
Alexis Ford
media@progyny.com

Investors:
James Hart
investors@progyny.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.